Marc M. Loriaux, M.D., PhD.
- click here
Marc Loriaux, M.D., Ph.D. joined the Department of Pathology and Medicine in July, 2003 after completing a fellowship in Hematopathology at OHSU. He will help to staff the diagnostic hematopathology service and continue his research in Dr. Brian Druker’s laboratory studying tyrosine kinases as possible therapeutic targets in the treatment of hematologic malignancies.
"A potential therapeutic strategy for chronic lymphocytic leukemia by combining idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor,"
"BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein,"
"A case study of personalized therapy for osteosarcoma,"
"Comparison of methods to identify aberrant expression patterns in individual patients: Augmenting our toolkit for precision medicine,"
"CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway,"